Clinical trials: Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT06715982
- Testing
- JAK Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu
Immune Checkpoint Inhibitor-Induced Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT07530224
- Testing
- treated with JAK inhibitors orally for 28 days
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu